发布时间: 2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New Drug (IND) application stage, while the other is a preclinical candidate.This agreement highlights the Company’s expertise in early-stage siRNA drug discovery and development, marking a significant m...
浏览次数:5
发布时间: 2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the initial dosing, marking the commencement of the Phase IV clinical stage.Efung Capital first invested in Oryzogen in 2016 and has continued to increase its commitment, participating in two consecutive fina...
浏览次数:4
发布时间: 2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the exclusive selected product in the confocal microscopy field for this batch, securing a “strong start” for the 15th Five-Year Plan with national-level authoritative certification. This achievement lays...
浏览次数:5
发布时间: 2026 - 02 - 27
Preface:Spring breezes blow strong as we spur our horses forward. Riding the momentum of the 2026 Spring Festival (Year of the Horse), Efung Capital received a series of good news this month: Insight Lifetech successfully listed on the Sci-Tech Innovation Board (STAR Market); three portfolio companies simultaneously advanced their Hong Kong IPOs, with all applications accepted for review.Meanwhile, more portfolio companies have achieved multi-point breakthroughs and advanced together in key sectors, writing a new chapter for China's biopharmaceutical industry with vigorous momentum.&#...
浏览次数:5
71页次4/18首页PREV12345678910...NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务